Literature DB >> 24485293

[CCAFU Recommendations 2013: Diagnosis, treatment, follow up of urological cancers].

M Soulié, P Coloby1, J Irani1, T Lebret, J-J Patard, C Pfister, P Richaud, J Rigaud, L Salomon.   

Abstract

INTRODUCTION: The objective of the 2013 recommendations performed by the different committees of CCAFU is to improve the management of urological cancers regarding diagnosis, clinical assessment and treatments in men and women.
MATERIAL AND METHODS: 2010 clinical guidelines were updated based on international AUA and EAU guidelines and on systematic literature search performed by each sub-Committee in Medline and PubMed databases to evaluate references, levels of evidence and grade of recommendation.
RESULTS: CCAFU clinical guidelines reply to the main clinical questions on management of urological cancers.
CONCLUSION: French clinical guidelines are updated every three years by CCAFU in accordance with the main international guidelines in onco-urology.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Level of proof; Niveaux de preuve; Onco-urologie; Onco-urology; Recommandations; Recommendations

Mesh:

Year:  2013        PMID: 24485293     DOI: 10.1016/S1166-7087(13)70046-0

Source DB:  PubMed          Journal:  Prog Urol        ISSN: 1166-7087            Impact factor:   0.915


  2 in total

1.  Criteria for indication and treatment modification in a cohort of patients with prostate cancer treated with hormone therapy.

Authors:  Thierry Lebret; Alain Ruffion; Igor Latorzeff; Marc Zerbib; Jean-Luc Moreau; Dominique Rossi; Nathalie Pello-Leprince-Ringuet; Valérie Perrot; Christophe Hennequin
Journal:  Ther Adv Urol       Date:  2018-10-24

2.  Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study.

Authors:  Jacques Médioni; Mario Di Palma; Aline Guillot; Dominique Spaeth; Christine Théodore
Journal:  BMC Cancer       Date:  2016-03-14       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.